このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

頭頸部がん患者における化学療法および免疫療法と併用したセミプリマブの研究

2026年11月17日 更新者:Memorial Sloan Kettering Cancer Center

切除可能で局所的に進行した頭頸部扁平上皮癌患者を対象とした、プラチナ 2 剤併用化学療法によるネオアジュバント セミプリマブとセツキシマブのパイロット研究

The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

40

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Lara Dunn, MD
  • 電話番号:646-608-3787
  • メール:dunnl1@mskcc.org

研究連絡先のバックアップ

研究場所

    • New Jersey
      • Basking Ridge、New Jersey、アメリカ、07920
        • 募集
        • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
        • コンタクト:
      • Middletown、New Jersey、アメリカ、07748
        • 募集
        • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
        • コンタクト:
          • Lara Dunn, MD
          • 電話番号:646-608-3787
      • Montvale、New Jersey、アメリカ、07645
        • 募集
        • Memorial Sloan Kettering Bergen (Limited Protocol Activities)
        • コンタクト:
          • Lara Dunn, MD
          • 電話番号:646-608-3787
    • New York
      • Commack、New York、アメリカ、11725
        • 募集
        • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)
        • コンタクト:
          • Laura Dunn, MD
          • 電話番号:646-608-3787
      • Harrison、New York、アメリカ、10604
        • 募集
        • Memorial Sloan Kettering Westchester (Limited Protocol Activities)
        • コンタクト:
          • Lara Dunn, MD
          • 電話番号:646-608-3787
      • New York、New York、アメリカ、10065
        • 募集
        • Memorial Sloan Kettering Cancer Center
        • コンタクト:
          • Lara Dunn, MD
          • 電話番号:646-608-3787
      • Rockville Centre、New York、アメリカ、11553
        • 募集
        • Memorial Sloan Kettering Nassau (Limited Protocol Activites)
        • コンタクト:
          • Laura Dunn, MD
          • 電話番号:646-608-3787

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck that has arisen from the oral cavity, oropharynx, nasal cavity, paranasal sinuses, larynx, or hypopharynx

  • Clinical stage T1, N2-3; T2, N1-3, T3/T4a, Any N (AJCC, 8th ed.) without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis, for which standard-of-care treatment would entail surgical resection with adjuvant radiation +/- chemotherapy.

    ° Patients with recurrent and multiple primary head and neck cancers that are surgically resectable are eligible if the patient did not receive prior radiation or systemic therapy.

  • Disease must be amenable to surgical resection.

  • The patient must be a surgical candidate.

  • Adequate organ and bone marrow function documented by:

    1. Hemoglobin > 9.0 g/dL
    2. Absolute neutrophil count (ANC) >1.5 x 10^9/L
    3. Platelet count >100 x 10^9/L
    4. Serum creatinine <1.5 upper limit of normal (ULN) or estimated creatinine clearance (CrCl) >30 mL/min
    5. Adequate hepatic function:
  • Total bilirubin <1.5 x upper limit of normal ULN)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 3 x ULN

  • Alkaline phosphatase (ALP) <2.5 x ULN Note: For patients with Gilbert syndrome, total bilirubin <3x ULN. Upper central must be documented appropriately as past medical history.

  • Men and woman >18 years old

  • Eastern cooperative oncology group performance status < 1 CPS ≥ 20 and

Inclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:

  • Pathologically (histologically) proven diagnosis of oral cavity squamous cell carcinoma HPV-negative by p16 or ISH
  • Clinical Stage will be limited to cT2 with cN0-N2b, cM0 with only 1 lymph node >2.0 cm in the short axis without evidence of distant metastasis (M0) based on PET/CT or CT chest, abdomen, and pelvis.
  • Curative intent surgical management is determined to require a free flap, mandibulectomy, glossectomy, or other significant surgical morbidity.

Exclusion Criteria:

  • Prior radiation and systemic therapy for a head and neck cancer.
  • Oral cavity cancer that is not amenable to surgical resection or the patient is not a surgical candidate.
  • Active or prior documented autoimmune or inflammatory disorders that have been treated with steroids or immunomodulator therapy in the past 5 years.

Exceptions: Patients with vitiligo, type 1 diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that is resolved, or psoriasis it does not require systemic treatment are permitted.

  • Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressant medications within 14 days of treatment on study.

  • Receipt of live attenuated vaccine within 30 days prior initiating treatment on study.

  • Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.

  • Any infection requiring hospitalization and/or intravenous antibiotic therapy within 2 weeks of the start of treatment.

  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency.

    1. Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350, either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection monitoring will be performed per local standards
    2. Patients with HBV (hepatitis B surface antigen positive; HBsAg+) who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for HBV) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months be on the last dose of Cemiplimab.
    3. Patients were HCV antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR, either spontaneously or in response to successful prior course of anti-HCV therapy) are permitted.
  • History of immune-related pneumonitis with the last 5 years.

  • History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of leuko-corticoids to assist with management.

  • Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.

  • Patients with a history of solid organ transplant (exception: corneal transplant)

  • Any medical comorbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that in the opinion of the investigator renders the patient unsuitable for participation in a clinical trial due to high safety risks.

  • Women with a positive serum or urine beta-hCG pregnancy test at screening/baseline visit. If positive, pregnancy must be ruled out by ultrasound for patient to be eligible.

  • Breast-feeding women

  • Women of childbearing potential who are sexually active and aren't willing to practice highly effective contraception prior to the first dose of Cemiplimab, during the study, and for at least 180 days after the last dose. Highly effective contraceptive measures include:

    1. Stable use of combined estrogen and progesterone containing hormonal contraception or progesterone and-only hormonal contraception associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening
    2. Intrauterine device; intrauterine hormone-releasing system
    3. Bilateral tubal ligation
    4. Vasectomized partner and/or
    5. Sexual abstinence

Exclusion criteria for the tertiary cohort will remain the same as prior with the following exceptions:

  • History of head and neck cancer. This includes patients who present with a recurrence of a previously treated oral cavity squamous cell carcinoma.
  • Synchronous primary squamous cell carcinomas of the oral cavity.
  • Presence of diffuse oral mucosa dysplasia or leukoplakia that per the judgement of the clinical investigator represents a clinically and independent significant risk of developing a second oral cavity primary

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Head and Neck Squamous Cell Cancer/HNSCC

Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.

Cisplatin 75mg/m2 AUC 5 on weeks 2, 5, and 8

Carboplatin AUC 5 on weeks 2, 5, and 8

Docetaxel 75mg/m2 on weeks 2, 5, and 8

Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10

Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37

Twenty-eight days (+ 7 days) following the 3rd cycle of neoadjuvant therapy, patients will then undergo definitive surgical resection of the primary site +/- neck dissection(s).

Post-operative radiation therapy +/- radiosensitizing agent(s) will be administered per standard-of-care based on pathologic staging of the surgical specimen. If there is an excellent response to treatment with a high degree of downstaging the addition of adjuvant radiation may be omitted if NCCN guidelines are met. If the pathologic stage following induction systemic therapy and surgery is ypT1-2N0 without the presence of adverse features that include positive margins or a combination of perineural invasion, vascular invasion, and a depth of invasion of >0.5mm, adjuvant radiation will not be administered, consistent with the NCCN guidelines [2]. Otherwise, patients will receive adjuvant RT-based treatment with standard radiation techniques.

If participants are unable to receive Docetaxel due to lack of insurance approval or due to an allergic reaction, Docetaxel can be substituted with Paclitaxel. Paclitaxel would be dosed at 90 mg/m2 on weeks 2, 3, 5, 6, 8 and 9.

他の名前:
  • タキソール
実験的:Secondary Cohort

Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.

Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10

Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37

実験的:Tertiary Cohort: Oral cavity squamous cell carcinoma (OCSCC)

A tertiary cohort of 20 patients with oral cavity squamous cell carcinoma (OCSCC)

Cetuximab 400mg/m2 on week 1, 250mg/m2 on weeks 2, 3, 4, 5, 6, 7, 8, 9, 10

Cemiplimab 350mg on weeks 2, 5, 8, 11; if adjuvant radiation +/- chemotherapy is omitted, Cemiplimab will be administered on weeks 16, 19, 22, 25, 28, 31, 34, 37

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of toxicities graded according to NCI CTCAE
時間枠:1 year

The primary endpoint is safety and tolerability, which will be evaluated by a description of observed adverse events by grades. All toxicities will be graded according to NCI CTCAE, Version5.0. The regimen will be deemed safe and well tolerated if there are 2 or fewer DLTs out of 10 patients enrolled. A DLT is defined as any non-hematologic grade 3 or greater adverse event as defined by CTCAE v5.0 that is thought to be related to the addition of Cemiplimab to the combination of a platinum-doublet with cetuximab.

1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Lara Dunn, MD、Memorial Sloan Kettering Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月20日

一次修了 (推定)

2027年6月20日

研究の完了 (推定)

2027年6月20日

試験登録日

最初に提出

2021年1月21日

QC基準を満たした最初の提出物

2021年1月21日

最初の投稿 (実際)

2021年1月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。